Elsevier

Maturitas

Volume 73, Issue 1, September 2012, Pages 61-67
Maturitas

Review
Nanomedicine for treatment of diabetes in an aging population: State-of-the-art and future developments

https://doi.org/10.1016/j.maturitas.2011.12.004Get rights and content

Abstract

Nowadays diabetes, especially type 2 diabetes (which is strongly related to the Western diet and life-style), has developed worldwide into an epidemic disease. Nanomedicine aims to provide novel tools for diagnosis, therapy and point-of-care management of patients.

Several nanotechnological approaches were developed to improve life quality for patients with insulin-dependent diabetes. They facilitate blood glucose management by non-invasive glucose measurement as well as insulin administration mainly by delivering the fragile protein as protected and targeted formulation via nasal or oral route.

In the present review the oral or nasal insulin delivery by polymeric nanoparticles is discussed with focus on physiological change either related to the disease, diabetes or age-related metabolic variations influencing insulin release and bioavailability. One critical point is that new generations of targeted nanoparticle based drugs are developed and optimized for certain metabolic conditions. These conditions may change with age or disease. The influence of age-related factors such as immaturity in very young age, metabolic and physiologic changes in old age or insufficient animal models are still under-investigated not only in nanomedicine but also generally in pharmacology.

Summarizing it can be noted that the bioavailability of insulin administered via routes others than subcutaneously is comparably low (max. 60%). Moreover factors like changed gut permeability as described for diabetes type 1 or other metabolic peculiarities such as insulin resistance in case of type 2 diabetes also play a role in affecting the development of novel nanoparticulated drug preparations and can be responsible for unsuccessful translation of promising animal results into human therapy.

In future insulin nanoparticle development for diabetes must consider not only requirements imposed by the drug but also metabolic changes inflicted by disease or by age. Moreover new approaches are required for prevention of the disease.

Introduction

The importance of nanomedicine to face the challenges imprinted on the society by an aging population to guarantee high life quality and health was recently highlighted in an editorial by Gabellieri and Frima [1]. While in this editorial they focused on the impact nanomedicine can have on treatment of neurodegenerative diseases the same holds true for other age-related disease such as diabetes with its world-wide epidemic spreading.

Diabetes mellitus (DM) is a disease which has become epidemic in the world, which is reflected by the fact that the total number of patients with DM is expected to rise from 171 million in 2000 to prognosticated 366 million in 2030 based on the data from 40 countries published by the WHO [2]. DM continues to increase in prevalence and impact. This causes an excess in healthcare expenditure, and finally a large economic burden through loss of productivity and foregone economic growth [3].

To complicate the picture many will not suffer from just one disease; they will, on average, be managing up to five co-morbidities by the age of 65 [4]. This does not include the side effects of diabetes, such as blindness due to diabetic retinopathy, or the complications of insulin management with multiple drugs to control cardiovascular disease. The burden to society is not caused by the disease, but the result of the complications of the disease when it is uncontrolled. Though the management of diabetes is now straight forward, before injectable insulin it was a death sentence. With many of the new control procedures people will live a long and relatively healthy life. With this we are starting to see long term consequences of disease that did not exist in the past because most diabetics did not live beyond their 60th year. Now there is no reason they cannot live into their 100s.

The two major forms of diabetes are type 1, an autoimmune-mediated destruction of pancreatic islet beta-cells and type 2 diabetes mellitus (T2DM) [3], [5]. It is in particular incidence of T2DM that has exploded over the last decades owing to an aging population in the developed world as well as a changed life-style and adaption to western nutrition in developing countries [6], [7]. The reasons for T2DM are not completely understood but seem to be closely related to physical inactivity and the resulting obesity [8]. In the past T2DM was a disease which occurred more often in the elderly and one of the bodily changes related to aging is a progressive increase in body fat [8]. Metabolically T2DM is due to an insufficient insulin secretion to cope with the increased blood glucose level [9] as well as the presence of insulin resistance. However, beta cell failure is the crucial factor, due to reduced beta cell mass and functional beta cell defects [10], [11].

More recent findings indicate that among the chain of events leading to the impairment of insulin secretion, some might be targeted by nanomedicine. Many changes at the gene and protein expression levels have been reported in type 2 diabetic pancreatic islets. Using oligonucleotide microarrays of pancreatic islets isolated from humans with type 2 diabetes versus normal glucose-tolerant controls, it has been found that 370 genes were differently expressed in the two groups [12]. Quantitative RT-PCR studies were performed in the same study, showing changes in the expression of genes known to be important in beta-cell function, including major decreases in the expression of HNF4alpha, insulin receptor, IRS2, Akt2, the transcription factor ARNT/HIF1beta (hydrocarbon nuclear receptor translocator/hypoxia-inducible factor 1β) and several glucose-metabolic-pathway genes. Successively, several genes encoding for the following proteins were found to be downregulated in type 2 diabetic islets by real-time RT-PCR: insulin, glucose transporter 1, glucose transporter 2, glucokinase, and molecules involved in insulin granules exocytosis [13], [14]. On the contrary, genes implicated in differentiation and proliferation pathways have been reported to be increased in diabetic islets, including PDX-1, Foxo-1, Pax-4, and TCF7L2 [13], [15], [16]. Furthermore, changes at the level of the expression of genes involved in regulating cell redox balance have been shown [17].

Some information is also available as for protein expression in type 2 diabetic islets. The amount of insulin has been reported to be decreased 30–40% in diabetic islet cells [13], [14]. The expression of AMP-activated kinase, IRS-2, PDX-1 (this latter at odds with gene expression data), and that of proteins involved in exocytosis was also found to be decreased in type 2 diabetic islets in comparison to non-diabetic samples [13], [14]. In addition, TCF7L2 protein expression was also found to be decreased in type 2 diabetic islets [18]. Interestingly, some data are available on type 2 diabetic islet protein profiling, as reported recently [19]. The data showed that in islets isolated from type 2 diabetic individuals the most activated pathways were pathways of cell arrest and apoptosis (p53, caspase, stress-activated).

Increased deposition of islet amyloid polypeptide (IAPP) in the islets could also contribute to beta cell dysfunction and death [20]. High concentrations of IAPP cause aggregation, fibril formation and eventually islet amyloidosis [20]. Recent evidence favours the concept that it is the process of amyloid fibril formation or the formation of toxic IAPP oligomers, rather than the deposit of mature fibrils, to be cytotoxic [11].

Other studies indicate an involvement of microRNAs in the development and prevalence of T2DM [21]. MicroRNA is a recently discovered group of non-coding but regulatory single-stranded RNAs of around 22 nucleotide length. They regulate gene expression by silencing, either by cleaving or repression, and target mRNA in a highly specific manner [21].

Recent findings showed that microRNA is involved in the process of glucose homeostasis in form of a “ribo-regulator” [22] and mainly inhibits the insulin exocytosis and alters the lipid metabolism, the link to obesity. A detailed description of the molecular mechanism of action can be found in the review article by Pandey and co-workers [21]. The profiling of the serum-derived microRNA seems to indicate in the direction of a novel class of biomarkers for the targeting of future generations of drug to diseased tissue [23]. A recently published work by Guay and collaborators is going in the same direction [24]. They studied T2DM and its effects on different diabetes affected tissues such as adipose tissue, liver and skeletal muscles in terms of differences in the microRNA profile. Moreover they clearly state that the changed microRNA profile is also reflected in the blood and hence can provide biomarkers to monitor onset [25] and development of T2DM [24]. Guay et al. [24] finally concluded that the microRNA can be a possible target for a gene-therapy curing type 2 diabetes.

In another work, Ohtsubo et al. [26] found that elevated levels of free fatty acids especially the palmitic acid lead to the nuclear exclusion and reduced expression of two transcription factors, connected to a specific glycosyltransferase responsible for the proper inclusion of the glucose transporter-2 into the beta-cell membrane and hence a loss of glucose-stimulated insulin secretion with all its consequences. The same pathway seems to be responsible for the increasing insulin resistance in the insulin target tissues such as liver, adipose tissue and skeletal muscles. They could show that an improvement of the conditions in terms of enforced glycosylation in the beta-cells leads to a general improvement also of the other insulin and glucose dependent tissues.

Why are we describing the reasons of T2DM in such detail? And what is changing with age? Because nanotechnology may provide the vehicles for targeted delivery of either siRNA, microRNA or DNA plasmids to correct insulin deficiency or novel drugs to dissolve diabetes related polypeptide amyloid fibers with strategies explored for beta-amyloid plaques in Alzheimer disease [27] or prion protein aggregates [28].

There are two great opportunities offered by nanomedicine, nanotechnology used for medical applications. One is the miniaturization of existing drug systems and to improve in this way the biocompatibility and bioavailability. The other is more groundbreaking. It uses nanomedicine for a sophisticated delivery of molecules which influences the disease origin rather than treating the symptoms and which never could be administered before. For the conventional medicine they were too valuable (low quantities available like hormones), too delicate (very fragile or immediate degradation like peptides or DNA), or too toxic (in larger quantities and untargeted delivery like toxins from animals). All these molecules now can be delivered with the new nanodrugs which require lower amounts of drugs, deliver preferentially only to the target organ or cell and protect the biological molecules during their travel throughout the body. But so far the nanomedicine for treatment of diabetes mellitus was used only to improve the existing administration forms of insulin and try to improve the life quality of DM patients by non-invasive administration and glucose monitoring.

Section snippets

Nanomedical approaches for non-invasive insulin substitution therapy

DM is associated with high morbidity and mortality, primarily mediated by the development of chronic vascular changes over time. In order to prolong the onset of these secondary symptoms a insulin replacement therapy is established standard treatment for the late-stage of T2DM as well as for type 1 diabetes. As the invasive multiple injections of precisely calculated amounts of insulin present a significant deterioration of the life quality of diabetic patients the first and best established

Conclusions

So far nanomedicine in the treatment of diabetes aims mainly to improve the life-quality of patients by providing a non-invasive insulin administration and glucose control. While the novel glucose detections systems promise a good opportunity to control the glucose level more frequently and hence allow a better insulin management the nanoparticulated insulin administration suffers mainly from its low bioavailability. It is to state that nanoparticles administered via the nasal or oral route

Outlook

So far few nanoparticle strategies were developed to target the intracellular accumulating human islet amyloid polypeptide (IAPP) and hence the IAPP induced beta-cell death which may be the reason for impaired insulin production in T2DM [60]. The first therapeutic approaches to inhibit the fibril formation of the IAPP by rifampicin failed leading to the conclusion that precursors such as oligomers are the cytotoxic form [11]. This can be a new approach for either the early diagnosis of the

Contributors

Silke Krol wrote the part about the nanoparticles and their interaction with the bio-interface.

Rutledge Ellis-Behnke wrote the part about the physiology in age and co-morbidities influencing NP uptake.

Piero Marchetti wrote the background information about diabetes and the cellular and genetic changes.

Competing interest

No competing interests.

Funding

S. Krol and P. Marchetti received a research grant from CariPisa.

Provenance of peer review

Commissioned and externally peer reviewed.

Acknowledgement

Piero Marchetti and Silke Krol are grateful by the financial support from CariPisa. Rutledge Ellis-Behnke thanks the Augenklinik, Medical Faculty Mannheim of the Ruprecht-Karls-University Heidelberg.

References (66)

  • A. Makhlof et al.

    Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery

    Eur J Pharm Sci

    (2011)
  • Y. Zhang et al.

    Preparation and evaluation of alginate-chitosan microspheres for oral delivery of insulin

    Eur J Pharm Biopharm

    (2011)
  • S.K. Lai et al.

    Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues

    Adv Drug Deliv Rev

    (2009)
  • C.B. Woitiski et al.

    Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles

    Eur J Pharm Sci

    (2010)
  • C. Damgé et al.

    Poly(epsilon-caprolactone)/eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes

    J Pharm Sci

    (2010)
  • C. Schleh et al.

    The influence of pulmonary surfactant on nanoparticulate drug delivery systems

    Eur J Pharm Biopharm

    (2011)
  • R.J. Mrsny

    Lessons from nature: “Pathogen-Mimetic” systems for mucosal nano-medicines

    Drug Deliv Rev

    (2009)
  • Z. Wu et al.

    Phenylboronic acid grafted chitosan as a glucose-sensitive vehicle for controlled insulin release

    J Pharm Sci

    (2011)
  • M. Hrynyk et al.

    Sustained prolonged topical delivery of bioactive human insulin for potential treatment of cutaneous wounds

    Int J Pharm

    (2010)
  • American Diabetes Association

    Diagnosis and classification of diabetes mellitus

    Diabetes Care

    (2011)
  • A.A. Khleif et al.

    Multiple comorbid conditions among middle-aged and elderly hemophilia patients: prevalence estimates and implications for future care

    J Aging Res

    (2011)
  • A. Misra et al.

    Obesity, the metabolic syndrome, and type 2 diabetes in developing countries: role of dietary fats and oils

    J Am Coll Nutr

    (2010)
  • A.A. Mangoni et al.

    Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications

    Br J Clin Pharmacol

    (2004)
  • S.I. Tschen et al.

    Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice

    Diabetes

    (2009)
  • J.J. Meier et al.

    Inhibition of human IAPP fibril formation does not prevent beta-cell death: evidence for distinct actions of oligomers and fibrils of human IAPP

    Am J Physiol Endocrinol Metab

    (2006)
  • S. Del Guerra et al.

    Functional and molecular defects of pancreatic islets in human type 2 diabetes

    Diabetes

    (2005)
  • C.G. Ostenson et al.

    Impaired gene and protein expression of exocytotic soluble N-ethylmaleimide attachment protein receptor complex proteins in pancreatic islets of type 2 diabetic patients

    Diabetes

    (2006)
  • T. Brun et al.

    The diabetes-linked transcription factor Pax-4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1

    Hum Mol Genet

    (2008)
  • V. Lyssenko et al.

    Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes

    J Clin Invest

    (2007)
  • P. Marchetti et al.

    Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin

    J Clin Endocrinol Metab

    (2004)
  • L. Shu et al.

    Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function

    Hum Mol Genet

    (2009)
  • H.K. Nyblom et al.

    Apoptotic, regenerative, and immune-related signaling in human islets from type 2 diabetes individuals

    J Proteome Res

    (2009)
  • R.A. Ritzel et al.

    Human islet amyloid polypeptide oligomers disrupt cell coupling, induce apoptosis, and impair insulin secretion in isolated human islets

    Diabetes

    (2007)
  • Cited by (15)

    • Nanomedicine for diabetes mellitus management

      2022, Applications of Nanotechnology in Drug Discovery and Delivery
    • Medical nanorobots: Design, applications and future challenges

      2019, Control Systems Design of Bio-Robotics and Bio-Mechatronics with Advanced Applications
    • Oral delivery of therapeutic protein/peptide for diabetes-Future perspectives

      2013, International Journal of Pharmaceutics
      Citation Excerpt :

      FDA has approved the incretin based therapy and the approval is given for 3 drugs which augments the glucagon like peptide-1 (GLP-1) production (Peters, 2010). Exhaustive and extensive reviews on oral insulin delivery systems adopting various approaches exist in the literature, including those on nanoparticles also (Owens et al., 2001; Damge et al., 2008; Khafagy et al., 2007; Iyer et al., 2010; Rekha and Sharma, 2009a,b; Krol et al., 2011). In this review the recent developments and current approaches in developing oral insulin delivery systems are over viewed.

    • Nanotheranostics for personalized medicine

      2012, Advanced Drug Delivery Reviews
      Citation Excerpt :

      This approach offers the advantages to improve drug therapeutic efficiency and to dramatically reduce toxicity and unspecific side effects, thus leading to possible future evolution in the management of severe diseases. Mainly, nanomedicines have found wide applications in the treatment of cancers [21], however neurodegenerative [22,23] and inflammatory/autoimmune diseases [24,25], diabetes [26,27], as well as lung [28], and cardiovascular affections [29,30], can benefit from the use of nanosized carriers for drug delivery. Nevertheless, despite extensive efforts on developing targeted drug delivery systems, up to now, only very few products have achieved success in the clinic and reached the marketplace.

    View all citing articles on Scopus
    View full text